Ken Ford, CMC Tech, LLC
Dr. Ken Ford has over 25 years of experience in product strategy, development, scale-up, submissions and tech ops support of solid dosage, sterile product (including vaccines, ophthalmics and lyophilized products), combination products and primary packaging development from pre-clinical through commercial manufacturing. He started his career at Merck where he held product development and pilot plant positions working on vaccines, sterile products, solid dosage products, combination products, primary package development and product stability prediction, including projects in France and Singapore. He helped develop several products including Gardasil® , RotaTeq® , Invanz® and Juvisync® . He led Shire (now Takeda) Ophthalmic product development which developed Xiidra® . After leading the transfer of Xiidra® from Takeda to Novartis, he joined Lyndra Therapeutics as Vice President of Manufacturing where he established Lyndra’s manufacturing group and internal clinical manufacturing capability. He is the Founder & Principal Consultant at CMC Tech, LLC where he advises biopharma companies on CMC strategy. Dr. Ford is an American Institute of Chemical Engineers (AIChE) Fellow active in PD2M, PTF & AMPc. He serves on the NCEES Professional Chemical Engineer Exam Committee and the University of Rhode Island Chemical Engineering Dept Industrial Steering Committee. He was the 2015 Delaware Valley Chemical Engineer of the Year, a 2009 AIChE Shining Star recipient and received multiple employer awards including the Shire (Takeda) CEO Award and a Merck Division Award. He is an active mentor for early career talent in the biopharma industry. Dr. Ford received his PhD in Chemical Engineering from Lehigh University, MS Chemical Engineering Practice from MIT and BS from the University of Rhode Island. He is also a licensed Professional Engineer